Open Access

REVIEW

Non-coding RNAs as potential mediators of resistance to lung cancer immunotherapy and chemotherapy

JIAHUI WANG^1,#, HONGCHENG GE^2,3,#, ZHENGYUAN YU^1,*, LINGZHI WU^1,*

1 Department of Medical Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China
2 The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China
3 Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310018, China

* Corresponding Authors: ZHENGYUAN YU. Email: ; LINGZHI WU. Email:
# These two authors contributed equally to this work

Oncology Research 2025, 33(5), 1033-1054. https://doi.org/10.32604/or.2024.058256

Received 08 September 2024; Accepted 18 November 2024; Issue published 18 April 2025

Abstract

Lung cancer is a common cause of cancer-related death globally. The majority of lung cancer patients initially benefit from chemotherapy and immunotherapy. However, as the treatment cycle progresses and the disease evolves, the emergence of acquired resistance leads to treatment failure. Many researches have shown that non-coding RNAs (ncRNAs) not only influence lung cancer progression but also act as potential mediators of immunotherapy and chemotherapy resistance in lung cancer, mediating drug resistance by regulating multiple targets and pathways. In addition, the regulation of immune response by ncRNAs is dualistic, forming a microenvironment for inhibits/promotes immune escape through changes in the expression of immune checkpoints. The aim of this review is to understand the effects of ncRNAs on the occurrence and development of lung cancer, focusing on the role of ncRNAs in regulating drug resistance of lung cancer.

---

Keywords

---